Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study
Purpose. To evaluate the efficacy and safety of a single intravitreal dexamethasone implant (DXI) combined with intravitreal antivascular endothelial growth factor (anti-VEGF) therapy, in patients with neovascular age-related macular degeneration (wet-AMD) resistant to conventional treatment. Method...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2018/5612342 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832551624327823360 |
|---|---|
| author | Ermete Giancipoli Antonio Pinna Francesco Boscia Gianluigi Zasa Giovanni Sotgiu Simone Dore Giuseppe D’Amico Ricci |
| author_facet | Ermete Giancipoli Antonio Pinna Francesco Boscia Gianluigi Zasa Giovanni Sotgiu Simone Dore Giuseppe D’Amico Ricci |
| author_sort | Ermete Giancipoli |
| collection | DOAJ |
| description | Purpose. To evaluate the efficacy and safety of a single intravitreal dexamethasone implant (DXI) combined with intravitreal antivascular endothelial growth factor (anti-VEGF) therapy, in patients with neovascular age-related macular degeneration (wet-AMD) resistant to conventional treatment. Methods. In this randomized, controlled pilot study, 16 eyes of 15 patients, unresponsive to anti-VEGF therapy, were enrolled and randomly assigned to two groups: DXI + anti-VEGF (treatment group: 11 eyes) and monthly anti-VEGF alone (control group: 5 eyes). Patients were treated at baseline and followed for 6 months. Best corrected visual acuity (BCVA), optical coherence tomography (OCT) parameters, and fluorescein angiography (FA) were evaluated. Results. Eight eyes (72.7%) in the treatment group and 2 eyes in the control group (40%) showed complete retinal fluid resorption (p=0.049). BCVA showed no significant change from baseline in both the treatment group and the control group (p=0.40 and p=0.29, respectively). Both median central foveal thickness (CFT) and median macular volume showed a greater reduction from baseline in the treatment group. Conclusion. In patients showing an incomplete response to anti-VEGF therapy, DXI combined with intravitreal anti-VEGF seems to improve retinal fluid resorption without functional advantage. This trial is registered with ACTRN12618001102268. |
| format | Article |
| id | doaj-art-b1b1f53f76bb4dcdad4f6ac580453109 |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-b1b1f53f76bb4dcdad4f6ac5804531092025-02-03T06:01:06ZengWileyJournal of Ophthalmology2090-004X2090-00582018-01-01201810.1155/2018/56123425612342Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot StudyErmete Giancipoli0Antonio Pinna1Francesco Boscia2Gianluigi Zasa3Giovanni Sotgiu4Simone Dore5Giuseppe D’Amico Ricci6Department of Biomedical Sciences, University of Sassari, Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, Ophthalmology Unit, University of Sassari, Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, Ophthalmology Unit, University of Sassari, Sassari, ItalyDepartment of Medical, Surgical, and Experimental Sciences, Ophthalmology Unit, University of Sassari, Sassari, ItalyAzienda Ospedaliero-Universitaria (AOU) di Sassari, Sassari, ItalyDepartment of Biomedical Sciences, Clinical Epidemiology and Medical Statistics Unit, University of Sassari, Sassari, ItalyDepartment of Biomedical Sciences, University of Sassari, Sassari, ItalyPurpose. To evaluate the efficacy and safety of a single intravitreal dexamethasone implant (DXI) combined with intravitreal antivascular endothelial growth factor (anti-VEGF) therapy, in patients with neovascular age-related macular degeneration (wet-AMD) resistant to conventional treatment. Methods. In this randomized, controlled pilot study, 16 eyes of 15 patients, unresponsive to anti-VEGF therapy, were enrolled and randomly assigned to two groups: DXI + anti-VEGF (treatment group: 11 eyes) and monthly anti-VEGF alone (control group: 5 eyes). Patients were treated at baseline and followed for 6 months. Best corrected visual acuity (BCVA), optical coherence tomography (OCT) parameters, and fluorescein angiography (FA) were evaluated. Results. Eight eyes (72.7%) in the treatment group and 2 eyes in the control group (40%) showed complete retinal fluid resorption (p=0.049). BCVA showed no significant change from baseline in both the treatment group and the control group (p=0.40 and p=0.29, respectively). Both median central foveal thickness (CFT) and median macular volume showed a greater reduction from baseline in the treatment group. Conclusion. In patients showing an incomplete response to anti-VEGF therapy, DXI combined with intravitreal anti-VEGF seems to improve retinal fluid resorption without functional advantage. This trial is registered with ACTRN12618001102268.http://dx.doi.org/10.1155/2018/5612342 |
| spellingShingle | Ermete Giancipoli Antonio Pinna Francesco Boscia Gianluigi Zasa Giovanni Sotgiu Simone Dore Giuseppe D’Amico Ricci Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study Journal of Ophthalmology |
| title | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
| title_full | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
| title_fullStr | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
| title_full_unstemmed | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
| title_short | Intravitreal Dexamethasone in Patients with Wet Age-Related Macular Degeneration Resistant to Anti-VEGF: A Prospective Pilot Study |
| title_sort | intravitreal dexamethasone in patients with wet age related macular degeneration resistant to anti vegf a prospective pilot study |
| url | http://dx.doi.org/10.1155/2018/5612342 |
| work_keys_str_mv | AT ermetegiancipoli intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT antoniopinna intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT francescoboscia intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT gianluigizasa intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT giovannisotgiu intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT simonedore intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy AT giuseppedamicoricci intravitrealdexamethasoneinpatientswithwetagerelatedmaculardegenerationresistanttoantivegfaprospectivepilotstudy |